Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prevalence of COVID-19 infection in TB clinics in Kampala, Uganda.
Otaalo B, Cevik M, Mwebesa E, Nabisere-Arinaitwe R, Zawedde-Muyanja S, Nampala J, Nanziri C, Alinaitwe L, Aber F, Bayigga J, Nankinga B, Laker E, Owarwo NC, Sabiiti W, Adakun S, Kirenga B, Turyahabwe S, Sloan DJ, Sekaggya-Wiltshire C. Otaalo B, et al. Among authors: sabiiti w. Int J Tuberc Lung Dis. 2023 Jun 1;27(6):481-483. doi: 10.5588/ijtld.23.0010. Int J Tuberc Lung Dis. 2023. PMID: 37231596 No abstract available.
Antibiotic dispensing practices during COVID-19 and implications for antimicrobial resistance (AMR): parallel mystery client studies in Uganda and Tanzania.
Olamijuwon E, Konje E, Kansiime C, Kesby M, Keenan K, Neema S, Asiimwe B, Mshana SE, Mushi MF, Loza O, Sunday B, Sandeman A, Sloan DJ, Benitez-Paez F, Mwanga JR, Sabiiti W, Holden MTG; CARE Consortium. Olamijuwon E, et al. Among authors: sabiiti w. Antimicrob Resist Infect Control. 2023 Feb 11;12(1):10. doi: 10.1186/s13756-022-01199-4. Antimicrob Resist Infect Control. 2023. PMID: 36774512 Free PMC article.
Treatment seeking and antibiotic use for urinary tract infection symptoms in the time of COVID-19 in Tanzania and Uganda.
Olamijuwon E, Keenan K, Mushi MF, Kansiime C, Konje ET, Kesby M, Neema S, Asiimwe B, Mshana SE, Fredricks KJ, Sunday B, Bazira J, Sandeman A, Sloan DJ, Mwanga JR, Sabiiti W, Holden MT; CARE Consortium. Olamijuwon E, et al. Among authors: sabiiti w. J Glob Health. 2024 Jan 19;14:05007. doi: 10.7189/jogh.14.05007. J Glob Health. 2024. PMID: 38236690 Free PMC article.
The role of multidimensional poverty in antibiotic misuse: a mixed-methods study of self-medication and non-adherence in Kenya, Tanzania, and Uganda.
Green DL, Keenan K, Fredricks KJ, Huque SI, Mushi MF, Kansiime C, Asiimwe B, Kiiru J, Mshana SE, Neema S, Mwanga JR, Kesby M, Lynch AG, Worthington H, Olamijuwon E, Abed Al Ahad M, Aduda A, Njeru JM, Mmbaga BT, Bazira J, Sandeman A, Stelling J, Gillespie SH, Kibiki G, Sabiiti W, Sloan DJ, Holden MTG; HATUA Consortium. Green DL, et al. Among authors: sabiiti w. Lancet Glob Health. 2023 Jan;11(1):e59-e68. doi: 10.1016/S2214-109X(22)00423-5. Lancet Glob Health. 2023. PMID: 36521953 Free article.
Effect of seven anti-tuberculosis treatment regimens on sputum microbiome: a retrospective analysis of the HIGHRIF study 2 and PanACEA MAMS-TB clinical trials.
Musisi E, Wyness A, Eldirdiri S, Dombay E, Mtafya B, Ntinginya NE, Heinrich N, Kibiki GS, Hoelscher M, Boeree M, Aarnoutse R, Gillespie SH, Sabiiti W; PanACEA consortium. Musisi E, et al. Among authors: sabiiti w. Lancet Microbe. 2023 Nov;4(11):e913-e922. doi: 10.1016/S2666-5247(23)00191-X. Epub 2023 Oct 10. Lancet Microbe. 2023. PMID: 37832571 Free article.
Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial.
Heinrich N, de Jager V, Dreisbach J, Gross-Demel P, Schultz S, Gerbach S, Kloss F, Dawson R, Narunsky K, Matt L, Wildner L, McHugh TD, Fuhr U, Aldana BH, Mouhdad C, Brake LT, Boeree MJ, Aarnoutse RE, Svensson EM, Gong X, P J Phillips P, Diacon AH, Hoelscher M; PanACEA-TB consortium. Heinrich N, et al. Lancet Microbe. 2024 Dec 26:100952. doi: 10.1016/j.lanmic.2024.07.015. Online ahead of print. Lancet Microbe. 2024. PMID: 39793592 Free article.
Triage test for all-oral drug-resistant tuberculosis (DR-TB) regimen: a phase IV study to assess effectiveness, feasibility, acceptability and cost-effectiveness of the Xpert MTB/XDR assay for rapid triage and treatment of DR-TB.
Naidoo K, Naidoo A, Abimiku AG, Tiemersma EW, Gebhard A, Hermans SM, Sloan DJ, Ruhwald M, Georghiou SB, Okpokoro E, Agbaje A, Yae K, Tollera G, Moga S, Feyt H, Kachoka T, Letsoalo MP, Cabibbe AM, Perumal R, Shunmugam L, Cirillo DM, Foraida S, Sabiiti W, Ntinginya NE, Mtafya B, Bedru A, Gillespie SH; TRiAD Study Consortium. Naidoo K, et al. Among authors: sabiiti w. BMJ Open. 2024 Nov 27;14(11):e084722. doi: 10.1136/bmjopen-2024-084722. BMJ Open. 2024. PMID: 39609025 Free PMC article.
64 results